Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL
Published
Conference Paper
Full Text
Duke Authors
Cited Authors
- Magbanua, MJM; Li, W; Wolf, DM; Yau, C; Hirst, GL; Brown-Swigart, L; Chien, AJ; Delson, AL; Gibbs, J; Aleshin, A; Zimmerman, B; Esserman, L; Hylton, N; Veer, LVT
Published Date
- June 1, 2020
Published In
- Poster Presentations Proffered Abstracts
Published By
Digital Object Identifier (DOI)
- 10.1158/1557-3265.liqbiop20-a50
Conference Name
- Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL